Vascular Endothelial Growth Factor Receptor-3

Download PDF

Recent Publications on Vascular Endothelial Growth Factor Receptor-3:
Molecular control of lymphatic metastasis. The metastatic spread of tumor cells is the most lethal aspect of cancer...	4th July, 2008	Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria	Ann N Y Acad Sci. 2008;1131:225-34. DOI Direct Link
Markers for microscopic imaging of lymphangiogenesis and angiogenesis. Imaging of lymphangiogenesis and angiogenesis requires robust and...	4th July, 2008	Cardiovascular Research Institute, Comprehensive Cancer Center, and	Ann N Y Acad Sci. 2008;1131:1-12. DOI Direct Link
Prox-1 Promotes Invasion of Kaposiform Hemangioendotheliomas. Kaposi's sarcoma (KS) is the most frequently occurring malignant tumor in...	27th June, 2008	[1] 1Department of Dermatology, Cutaneous Biology Research Center, Boston,	J Invest Dermatol. 2008 Jun 26;. DOI Direct Link
Activation of Akt through gp130 receptor signaling is required for KSHV induced lymphatic reprogramming of endothelial cells. Kaposi's sarcoma (KS) is the most common tumor of AIDS patients...	27th June, 2008	Molecular and Cellular Biology Program, University of Washington, Seattle,	J Virol. 2008 Jun 25;. DOI Direct Link
Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells. Solid tumors express a range of factors required to sustain their growth...	20th June, 2008		Cancer Cell. 2008 Jun;13(6):557-60. DOI Direct Link
→View more research publications.

BioNews Results for Vascular Endothelial Growth Factor Receptor-3:
Crohn's disease: beyond antagonists of tumour necrosis factor	Lancet:  Jul 4 2008 12:44AM Matching: vascular endothelial growth factor receptor 3
Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Cal	Journal of the American Medical Association:  Jun 10 2008 9:35PM Matching: vascular endothelial growth factor receptor 3
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies	PharmCast:  May 16 2008 4:13AM Matching: vascular endothelial growth factor receptor 3

Vascular Endothelial Growth Factor Receptor-3 Clinical Trials:
Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients	Melanoma Intervention: Drug: Fibrin Sealant

Vascular Endothelial Growth Factor Receptor-3 Patents:
US Patent No.	Title
7227005	Vascular endothelial growth factor 2
6610484	Identifying material from a breast duct
6689352	Method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
6764820	Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
6824777	Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
→View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Vascular Endothelial Growth Factor Receptor-3 scientists - we have details of around 42 individuals working on Vascular Endothelial Growth Factor Receptor-3 .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.